Abstract:Endothelial dysfunction predisposing to cardiovascular diseases is defined as an imbalance in the production of vasodilating factors, such as nitric oxide (NO), and vasoconstrictive factors. To insure its physiological role, NO, a radical with very short half-life, requires to be stored and transported to its action site. S-nitrosothiols (RSNOs) like S-nitrosoglutathione (GSNO) represent the main form of NO storage within the vasculature. The NO store formed by RSNOs is still bioavailable to trigger vasorelaxation. In this way, RSNOs are an emerging class of NO donors with a potential to restore NO bioavailability within cardiovascular disorders. The aim of this study was to compare S-nitrosothiols ability, formed of peptide (glutathione) like the physiologic GSNO or derived from amino acids (cysteine, valine) like the synthetics S-nitroso-N-acetylcysteine (NACNO) and S-nitroso-N-acetylpenicillamine (SNAP), respectively, to produce a vascular store of NO either in endothelium-intact or endothelium-removed aortae in order to evaluate whether RSNOs can be used as therapeutics to compensate endothelial dysfunction. Sodium nitroprusside (SNP), a marketed drug already in clinics, was used as a non-RSNO NO-donor. Endothelium-intact or endothelium-removed aortae, isolated from normotensive Wistar rats, were exposed to RSNOs or SNP. Then, NO-derived (NOx) species, representing the NO store inside the vascular wall, were quantified using the diaminonaphthalene probe coupled to mercuric ions. The bioavailability of the NO store and its ability to induce vasodilation was tested using N-acetylcysteine, then its ability to counteract vasoconstriction was challenged using phenylephrine (PHE). All the studied RSNOs were able to generate a NO store materialized by a three to five times increase in NOx species inside aortae. NACNO was the most potent RSNO to produce a vascular NO store bioavailable for vasorelaxation and the most efficient to induce vascular hyporeactivity to PHE in endothelium-removed aortae. GSNO and SNAP were equivalent and more efficient than SNP. In endothelium-intact aortae, the NO store was also formed whereas it seemed less available for vasorelaxation and did not influence PHE-induced vasoconstriction. In conclusion, RSNOs - NACNO in a better extent - are able to restore NO bioavailability as a functional NO store within the vessel wall, especially when the endothelium is removed. This was associated with a hyporeactivity to the vasoconstrictive agent phenylephrine. Treatment with RSNOs could present a benefit to restore NO-dependent functions in pathological states associated with injured endothelium.

Progress in sodium nitrite based therapies for ischaemic diseases

Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases

Nitrite Anion Therapy Protects Against Chronic Ischemic Tissue Injury in db/db Diabetic Mice in a NO/VEGF-Dependent Manner

Targeting Nitrosative Stress as a Therapeutic Strategy for Neurovascular Protection in Brain Ischemia

Advances in Nitric Oxide Regulators for the Treatment of Ischemic Stroke

Design, Synthesis, and Biological Evaluation of Organic Nitrite (NO2-) Donors As Potential Anticerebral Ischemia Agents.

Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications

Abstract W P109: Nitrosative Stress Preconditioning Ameliorated Neurovascular Injury in Stroke

Progress in tolerance of nitrate

A Novel Ultrasound‐Responsive Biomimetic Nanoparticle for Targeted Delivery and Controlled Release of Nitric Oxide to Attenuate Myocardial Ischemia Reperfusion Injury

Nitric oxide in the cardio-cerebrovascular system: Source, regulation and application

Dietary nitrate biochemistry and physiology. An update on clinical benefits and mechanisms of action

[Progress in the Studies on Neuronal Nitric Oxide Synthase Inhibitors].

Facilitating Nitrite-Derived S-Nitrosothiol Formation in the Upper Gastrointestinal Tract in the Therapy of Cardiovascular Diseases

Progresses in nitrate biotransformation and tolerance mechanisms

Reducing Ischemia/Reperfusion Injury by the Targeted Delivery of Nitric Oxide from Magnetic-Field-Induced Localization of S-Nitrosothiol-Coated Paramagnetic Nanoparticles

One-electron reduction triggered nitric oxide release for ischemia-reperfusion protection

Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis

Specificity of Inducible Nitric-Oxide Synthase Inhibitors: Prospects for Their Clinical Therapy.

S-Nitrosothiols as potential therapeutics to induce a mobilizable vascular store of nitric oxide to counteract endothelial dysfunction

Nitric oxide synthase inhibitors and cerebral ischemia